Your browser doesn't support javascript.
loading
Assessing the time-to-removal of totally implantable venous access devices comparing valved-versus open-ended catheters in patients treated with chemotherapy.
Amroun, Koceila; Brugel, Mathias; Rhaiem, Rami; Teuma, Lugdivine; Vannieuwenhuyse, Geoffrey; Lipere, Audrey; Brenet, Esteban; Kianmanesh, Reza; Bouché, Olivier.
Afiliação
  • Amroun K; Department of Digestive and Endocrine surgery, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est, France.
  • Brugel M; Department of Digestive Oncology, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est, France.
  • Rhaiem R; Department of Digestive and Endocrine surgery, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est, France.
  • Teuma L; Department of Digestive and Endocrine surgery, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est, France.
  • Vannieuwenhuyse G; Department of Obstetrics and Gynaecology, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est, France.
  • Lipere A; Department of Obstetrics and Gynaecology, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est, France.
  • Brenet E; Department of Otorhinolaryngology, Head and Neck surgery, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est France.
  • Kianmanesh R; Department of Digestive and Endocrine surgery, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est, France.
  • Bouché O; Department of Digestive Oncology, CHU Reims, University of Reims Champagne Ardenne (URCA), Reims, Grand Est, France.
J Vasc Access ; : 11297298231223539, 2024 Jan 11.
Article em En | MEDLINE | ID: mdl-38205615
ABSTRACT

BACKGROUND:

Totally IntraVenous Acess Devices (TIVAD) are used to have long-term bloodstream access. The catheter connected to the subcutaneous chamber may be valved (TIVAD-V) or open-ended (TIVAD-O). Infectious and occlusion complications require the removal of the TIVAD. We compared the two types of catheters (TIVAD-V and TIVAD-O) in terms of time-to-removal and complication rates.

METHODS:

A retrospective study of 636 patients treated for any malignancy using a TIVAD were included. TIVAD complication was defined as the occurrence of infection or occlusion requiring TIVAD removal. Risk factors of complications and time-to-removal of TIVAD were assessed by a Cox proportional hazard analysis.

RESULTS:

A total of 55 TIVADs (8.7%) were removed including 47 for infection and eight for occlusion in 54 months. There was no significant difference in the frequency of complications between TIVAD-V and TIVAD-O. There was no significant difference in time-to-removal between TIVAD-V and TIVAD-O (17.0 months, IQR [10.5-25.0] and 18.4 months, IQR [11.5-22.9], p = 0.345, respectively).

CONCLUSION:

There was no difference between TIVAD with valved and open catheter in terms of complications and time-to-removal in patients treated by chemotherapy.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2024 Tipo de documento: Article